Compared with ordinary formulations, inhalants have their particularities in dosage form, device and mode of action, high barriers to research and development of inhalation drug delivery, involving multidisciplinary integration, and the accuracy of the obtained results may be reduced if the evaluation method of inhalant bioequivalence is carried out according to the ordinary dosage form, so the evaluation of inhalant bioequivalence is challenging.
In recent years, with the aging of China and the acceleration of urbanization, the incidence of respiratory diseases is on the rise. With the advantages of rapid effect and few side effects of inhalation drug delivery, the market is rising normally and rapidly. However, the relevant guidelines for the bioequivalence evaluation of inhalants have not been formally issued in China, which brings certain limitations to relevant research. The inhalant Conference presents wonderful content from in vivo and in vitro bioequivalence evaluation, inhalation drug delivery devices, research and development, regulations and policies, and data analysis.
